CORDIS

EU research results

CORDIS

Biomarker Enterprise to Attack DKD - Sofia ref.: 115974

Fact Sheet

Reporting

Results

Objective

Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence have reached epidemic dimensions in recent years. Unfortunately, there are no effective means to prevent or cure DKD, the few existing treatments have limited effect and very few alternative therapies have emerged in the past years. Lack of new predictive and prognostic biomarkers for a more accurate patient stratification, limited access to kidney tissue from patients at various stages of DKD as well as novel model systems to better understand the pathogenesis of the disease, are likely reasons for the stagnating development of new treatments.

The BEAt-DKD consortium combines outstanding basic and translational researchers in nephropathy, diabetes, kidney model systems, imaging techniques and systems biology, and includes leaders of diabetes and kidney disease-relevant
IMI1, FP7 and US consortia, like SUMMIT, KIDNEYCONNECT, Syskid, CPROBE and C-Path, in an unprecedented search for new and better biomarkers for DKD, through a better understanding of the disease.

Jointly, the partners have access to vast and very relevant clinical cohorts and trials, state-of-the-art analysis and imaging techniques, novel model systems and the long-standing experience and networks to make this collaboration a success. By involving regulatory agencies throughout the project, BEAt-DKD aims at making the introduction and acceptance of new tools as efficient as possible.

The overall goals of BEAt-DKD are (1) to provide a holistic systems medicine view of the pathogenesis of DKD with the aim to identify targetable mechanisms and pathways underlying initiation and progression of DKD, applying a novel sub-classification of diabetes, and (2) to identify and validate biomarkers of disease progression and treatment responses representing first steps towards precision medicine in the management of DKD.

Programme(s)

H2020-EU.3.1.7. - Innovative Medicines Initiative 2 (IMI2)

Topic(s)

IMI2-2015-05-02 - Diabetic Kidney Disease Biomarkers (DKD-BM)

Call for proposal

H2020-JTI-IMI2-2015-05-two-stage

See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

LUNDS UNIVERSITET

Address

Paradisgatan 5c
22100 Lund

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 110 937

Contact the organisation

Participants (30)

Sort alphabetically

Sort by EU Contribution

Expand all

HELSINGIN YLIOPISTO

Finland

EU Contribution

€ 800 000

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 2 100 000

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 900 000

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 200 000

UNIVERSITY OF DUNDEE

United Kingdom

EU Contribution

€ 655 000

THE UNIVERSITY OF EXETER

United Kingdom

EU Contribution

€ 555 000

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

EU Contribution

€ 150 000

TURUN YLIOPISTO

Finland

EU Contribution

€ 320 000

UNIVERSITAETSKLINIKUM FREIBURG

Germany

EU Contribution

€ 70 000

UNIVERSITY OF BRISTOL

United Kingdom

EU Contribution

€ 500 000

UNIVERSITY OF LEEDS

United Kingdom

EU Contribution

€ 860 000

UNIVERSITY OF HULL

United Kingdom

EU Contribution

€ 250 000

CHU HOPITAUX DE BORDEAUX

France

EU Contribution

€ 460 000

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 500 000

MEDIZINISCHE UNIVERSITAT INNSBRUCK

Austria

EU Contribution

€ 895 000

KLINIKUM DER UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 360 000

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 950 000

UNIVERSITA DEGLI STUDI DI BARI ALDO MORO

Italy

EU Contribution

€ 620 000

LIPOTYPE

Germany

EU Contribution

€ 300 000

University of Michigan/Autophagy Journal

United States

SIB INSTITUT SUISSE DE BIOINFORMATIQUE

Switzerland

JDRF INTERNATIONAL

United States

ABBVIE INC

United States

SANOFI-AVENTIS DEUTSCHLAND GMBH

Germany

ASTELLAS PHARMA EUROPE BV

Netherlands

Eli Lilly and Company Limited

United Kingdom

Bayer Pharma AG

Germany

NOVO NORDISK A/S

Denmark

BOEHRINGER INGELHEIM INTERNATIONALGMBH

Germany

UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF

Germany

EU Contribution

€ 1 530 000

Project information

BEAt-DKD

Grant agreement ID: 115974

Project website

Status

Ongoing project

Start date

1 September 2016
End date

31 August 2021

Funded under:

H2020-EU.3.1.7.

Overall budget:

€ 30 960 037
EU contribution

€ 15 085 937

Coordinated by:

LUNDS UNIVERSITET

Sweden

Periodic Reporting for period 2 - BEAt-DKD (Biomarker Enterprise to Attack DKD - Sofia ref.: 115974)

Reporting period: 2017-09-01 to 2018-08-31

Summary of the context and overall objectives of the project

Diabetic kidney disease (DKD) is the leading cause of end stage renal disease, and its global incidence and prevalence have reached epidemic dimensions. There are no effective means to prevent or cure DKD may be due to: (i) the current diagnosis of diabetes based on one metabolite, glucose, which is inaccurate and not useful in predicting disease outcome and choice of therapy; (ii) the consequences of early dysglycemia or metabolic memory for development of DKD have often been ignored; (iii) histological analysis is not usually used to differentiate DKD from CKD of other aetiology; (iv) unsuccessful identification of novel biomarkers, with micro-/macroalbuminuria remaining among the best predictors of DKD in addition to the decline in glomerular filtration rate. Few studies have attempted to explore the full potential of urine and plasma as sources of kidney biomarkers or to associate markers with kidney biopsy analyses.

The overall goals of Biomarker Enterprise to Attack DKD (BEAt-DKD) are:
1. to provide a holistic systems medicine view of the pathogenesis of DKD with the aim to identify targetable mechanisms and pathways underlying initiation and progression of DKD, applying a novel sub-classification of diabetes, and
2. to identify and validate biomarkers of disease progression and treatment responses representing first steps towards precision medicine in the management of DKD.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Logo

Project information

BEAt-DKD

Grant agreement ID: 115974

Project website

Status

Ongoing project

Start date

1 September 2016
End date

31 August 2021

Funded under:

H2020-EU.3.1.7.

Overall budget:

€ 30 960 037
EU contribution

€ 15 085 937

Coordinated by:

LUNDS UNIVERSITET

Deliverables

Documents, reports (1)

White paper on strengths and weaknesses of using biomarker panels (or multiple biomarker scores) as risk stratifiers, as targets in drug development and as surrogate endpoints for regulatory approval

Migration

Publications

Peer reviewed articles (38)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era

Author(s): Hiddo J. L. Heerspink, James List, Vlado Perkovic

Published in: Diabetes, Obesity and Metabolism, Issue 20, 2018, Page(s) 14-18, ISSN 1462-8902

DOI: 10.1111/dom.13417

Molecular, histological, and clinical phenotyping of diabetic nephropathy: valuable complementary information?

Author(s): Paul Perco, Gert Mayer

Published in: Kidney International, Issue 93/2, 2018, Page(s) 308-310, ISSN 0085-2538

DOI: 10.1016/j.kint.2017.10.026

The WD40-domain containing protein CORO2B is specifically enriched in glomerular podocytes and regulates the ventral actin cytoskeleton

Author(s): M. Rogg, M. Yasuda-Yamahara, A. Abed, P. Dinse, M. Helmstädter, A. C. Conzelmann, J. Frimmel, D. Sellung, M. L. Biniossek, O. Kretz, F. Grahammer, O. Schilling, T. B. Huber, C. Schell

Published in: Scientific Reports, Issue 7/1, 2017, ISSN 2045-2322

DOI: 10.1038/s41598-017-15844-1

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; apost hoc analysis of the PLANET trials

Author(s): Nienke M A Idzerda, Michelle J Pena, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J L Heerspink

Published in: Nephrology Dialysis Transplantation, 2018, ISSN 0931-0509

DOI: 10.1093/ndt/gfy159

Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes

Author(s): Andreas Heinzel, Michael Kammer, Gert Mayer, Roman Reindl-Schwaighofer, Karin Hu, Paul Perco, Susanne Eder, Laszlo Rosivall, Patrick B. Mark, Wenjun Ju, Matthias Kretzler, Peter Gilmour, Jonathan M. Wilson, Kevin L. Duffin, Moustafa Abdalla, Mark I. McCarthy, Georg Heinze, Hiddo L. Heerspink, Andrzej Wiecek, Maria F. Gomez, Rainer Oberbauer

Published in: Diabetes Care, Issue 41/9, 2018, Page(s) 1947-1954, ISSN 0149-5992

DOI: 10.2337/dc18-0532

A Multi-layered Quantitative In Vivo Expression Atlas of the Podocyte Unravels Kidney Disease Candidate Genes

Author(s): Markus M. Rinschen, Markus Gödel, Florian Grahammer, Stefan Zschiedrich, Martin Helmstädter, Oliver Kretz, Mostafa Zarei, Daniela A. Braun, Sebastian Dittrich, Caroline Pahmeyer, Patricia Schroder, Carolin Teetzen, HeonYung Gee, Ghaleb Daouk, Martin Pohl, Elisa Kuhn, Bernhard Schermer, Victoria Küttner, Melanie Boerries, Hauke Busch, Mario Schiffer, Carsten Bergmann, Marcus Krüger, Friedhelm Hildebrandt, Joern Dengjel, Thomas Benzing, Tobias B. Huber

Published in: Cell Reports, Issue 23/8, 2018, Page(s) 2495-2508, ISSN 2211-1247

DOI: 10.1016/j.celrep.2018.04.059

Prolonged exposure of mouse and human podocytes to insulin induces insulin resistance through lysosomal and proteasomal degradation of the insulin receptor

Author(s): Abigail C. Lay, Jenny A. Hurcombe, Virginie M. S. Betin, Fern Barrington, Ruth Rollason, Lan Ni, Lawrence Gillam, Grace M. E. Pearson, Mette V. Østergaard, Hellyeh Hamidi, Rachel Lennon, Gavin I. Welsh, Richard J. M. Coward

Published in: Diabetologia, Issue 60/11, 2017, Page(s) 2299-2311, ISSN 0012-186X

DOI: 10.1007/s00125-017-4394-0

Enhanced insulin receptor, but not PI3K, signalling protects podocytes from ER stress

Author(s): Kathryn L. Garner, Virginie M. S. Betin, Vanda Pinto, Mark Graham, Emmanuelle Abgueguen, Matt Barnes, David C. Bedford, Craig A. McArdle, Richard J. M. Coward

Published in: Scientific Reports, Issue 8/1, 2018, ISSN 2045-2322

DOI: 10.1038/s41598-018-22233-9

An integrative systems biology approach for precision medicine in diabetic kidney disease

Author(s): Skander Mulder, Habib Hamidi, Matthias Kretzler, Wenjun Ju

Published in: Diabetes, Obesity and Metabolism, Issue 20, 2018, Page(s) 6-13, ISSN 1462-8902

DOI: 10.1111/dom.13416

ARP3 Controls the Podocyte Architecture at the Kidney Filtration Barrier

Author(s): Christoph Schell, Benedikt Sabass, Martin Helmstaedter, Felix Geist, Ahmed Abed, Mako Yasuda-Yamahara, August Sigle, Jasmin I. Maier, Florian Grahammer, Florian Siegerist, Nadine Artelt, Nicole Endlich, Dontscho Kerjaschki, Hans-Henning Arnold, Jörn Dengjel, Manuel Rogg, Tobias B. Huber

Published in: Developmental Cell, Issue 47/6, 2018, Page(s) 741-757.e8, ISSN 1534-5807

DOI: 10.1016/j.devcel.2018.11.011

Treating diabetic complications; from large randomized clinical trials to precision medicine

Author(s): Hiddo J. L. Heerspink, Dick de Zeeuw

Published in: Diabetes, Obesity and Metabolism, Issue 20, 2018, Page(s) 3-5, ISSN 1462-8902

DOI: 10.1111/dom.13418

Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables

Author(s): Emma Ahlqvist, Petter Storm, Annemari Käräjämäki, Mats Martinell, Mozhgan Dorkhan, Annelie Carlsson, Petter Vikman, Rashmi B Prasad, Dina Mansour Aly, Peter Almgren, Ylva Wessman, Nael Shaat, Peter Spégel, Hindrik Mulder, Eero Lindholm, Olle Melander, Ola Hansson, Ulf Malmqvist, Åke Lernmark, Kaj Lahti, Tom Forsén, Tiinamaija Tuomi, Anders H Rosengren, Leif Groop

Published in: The Lancet Diabetes & Endocrinology, Issue 6/5, 2018, Page(s) 361-369, ISSN 2213-8587

DOI: 10.1016/S2213-8587(18)30051-2

AIF1L regulates actomyosin contractility and filopodial extensions in human podocytes

Author(s): Mako Yasuda-Yamahara, Manuel Rogg, Kosuke Yamahara, Jasmin I. Maier, Tobias B. Huber, Christoph Schell

Published in: PLOS ONE, Issue 13/7, 2018, Page(s) e0200487, ISSN 1932-6203

DOI: 10.1371/journal.pone.0200487

Novel avenues for drug discovery in diabetic kidney disease

Author(s): Matthew D. Breyer, Matthias Kretzler

Published in: Expert Opinion on Drug Discovery, Issue 13/1, 2017, Page(s) 65-74, ISSN 1746-0441

DOI: 10.1080/17460441.2018.1398731

Cilia‐localized LKB1 regulates chemokine signaling, macrophage recruitment, and tissue homeostasis in the kidney

Author(s): Amandine Viau, Frank Bienaimé, Kamile Lukas, Abhijeet P Todkar, Manuel Knoll, Toma A Yakulov, Alexis Hofherr, Oliver Kretz, Martin Helmstädter, Wilfried Reichardt, Simone Braeg, Tom Aschman, Annette Merkle, Dietmar Pfeifer, Verónica I Dumit, Marie‐Claire Gubler, Roland Nitschke, Tobias B Huber, Fabiola Terzi, Jörn Dengjel, Florian Grahammer, Michael Köttgen, Hauke Busch, Melanie Boerries, Gerd Walz, Antigoni Triantafyllopoulou, E Wolfgang Kuehn

Published in: The EMBO Journal, Issue 37/15, 2018, Page(s) e98615, ISSN 0261-4189

DOI: 10.15252/embj.201798615

Diverging impact of cell fate determinants Scrib and Llgl1 on adhesion and migration of hematopoietic stem cells

Author(s): Banaja P. Dash, Tina M. Schnöder, Carolin Kathner, Juliane Mohr, Sönke Weinert, Carolin Herzog, Parimala Sonika Godavarthy, Costanza Zanetti, Florian Perner, Rüdiger Braun-Dullaeus, Björn Hartleben, Tobias B. Huber, Gerd Walz, Michael Naumann, Sarah Ellis, Valera Vasioukhin, Thilo Kähne, Daniela S. Krause, Florian H. Heidel

Published in: Journal of Cancer Research and Clinical Oncology, Issue 144/10, 2018, Page(s) 1933-1944, ISSN 0171-5216

DOI: 10.1007/s00432-018-2724-3

Urinary extracellular vesicles. A promising shortcut to novel biomarker discoveries

Author(s): Karina Barreiro, Harry Holthofer

Published in: Cell and Tissue Research, Issue 369/1, 2017, Page(s) 217-227, ISSN 0302-766X

DOI: 10.1007/s00441-017-2621-0

DNA Methyltransferase 1 Controls Nephron Progenitor Cell Renewal and Differentiation

Author(s): Nicola Wanner, Julia Vornweg, Alexander Combes, Sean Wilson, Julia Plappert, Gesa Rafflenbeul, Victor G. Puelles, Raza-Ur Rahman, Timur Liwinski, Saskia Lindner, Florian Grahammer, Oliver Kretz, Mary E. Wlodek, Tania Romano, Karen M. Moritz, Melanie Boerries, Hauke Busch, Stefan Bonn, Melissa H. Little, Wibke Bechtel-Walz, Tobias B. Huber

Published in: Journal of the American Society of Nephrology, Issue 30/1, 2018, Page(s) 63-78, ISSN 1046-6673

DOI: 10.1681/asn.2018070736

Renal biopsy-driven molecular target identification in glomerular disease

Author(s): Maja T. Lindenmeyer, Matthias Kretzler

Published in: Pflügers Archiv - European Journal of Physiology, Issue 469/7-8, 2017, Page(s) 1021-1028, ISSN 0031-6768

DOI: 10.1007/s00424-017-2006-y

Cytoprotective activated protein C averts Nlrp3 inflammasome–induced ischemia-reperfusion injury via mTORC1 inhibition

Author(s): Sumra Nazir, Ihsan Gadi, Moh’d Mohanad Al-Dabet, Ahmed Elwakiel, Shrey Kohli, Sanchita Ghosh, Jayakumar Manoharan, Satish Ranjan, Fabian Bock, Ruediger C. Braun-Dullaeus, Charles T. Esmon, Tobias B. Huber, Eric Camerer, Chris Dockendorff, John H. Griffin, Berend Isermann, Khurrum Shahzad

Published in: Blood, Issue 130/24, 2017, Page(s) 2664-2677, ISSN 0006-4971

DOI: 10.1182/blood-2017-05-782102

Personalized medicine in diabetic kidney disease

Author(s): Nienke M.A. Idzerda, Michelle J. Pena, Hiddo J.L. Heerspink

Published in: Current Opinion in Nephrology and Hypertension, 2018, Page(s) 1, ISSN 1062-4821

DOI: 10.1097/MNH.0000000000000447

Residual urinary extracellular vesicles in ultracentrifugation supernatants after hydrostatic filtration dialysis enrichment

Author(s): Luca Musante, Dorota Tataruch-Weinert, Dontscho Kerjaschki, Michael Henry, Paula Meleady, Harry Holthofer

Published in: Journal of Extracellular Vesicles, Issue 6/1, 2017, Page(s) 1267896, ISSN 2001-3078

DOI: 10.1080/20013078.2016.1267896

P2Y2R Signaling Is Involved in the Onset of Glomerulonephritis

Author(s): Laura Rennert, Stefan Zschiedrich, Lukas Sandner, Björn Hartleben, Sanja Cicko, Cemil Korcan Ayata, Charlotte Meyer, Andreas Zech, Robert Zeiser, Tobias B. Huber, Marco Idzko, Florian Grahammer

Published in: Frontiers in Immunology, Issue 9, 2018, ISSN 1664-3224

DOI: 10.3389/fimmu.2018.01589

Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis

Author(s): Carole Henique, Guillaume Bollée, Xavier Loyer, Florian Grahammer, Neeraj Dhaun, Marine Camus, Julien Vernerey, Léa Guyonnet, François Gaillard, Hélène Lazareth, Charlotte Meyer, Imane Bensaada, Luc Legrès, Takashi Satoh, Shizuo Akira, Patrick Bruneval, Stefanie Dimmeler, Alain Tedgui, Alexandre Karras, Eric Thervet, Dominique Nochy, Tobias B. Huber, Laurent Mesnard, Olivia Lenoir, Pierre-Louis Tharaux

Published in: Nature Communications, Issue 8/1, 2017, ISSN 2041-1723

DOI: 10.1038/s41467-017-01885-7

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

Author(s): Nienke M. A. Idzerda, Frederik Persson, Michelle J. Pena, Barry M. Brenner, Patrick Brunel, Nish Chaturvedi, John J. McMurray, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J. L. Heerspink

Published in: Diabetes, Obesity and Metabolism, 2018, ISSN 1462-8902

DOI: 10.1111/dom.13465

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy

Author(s): Adeera Levin, Marcello Tonelli, Joseph Bonventre, Josef Coresh, Jo-Ann Donner, Agnes B Fogo, Caroline S Fox, Ron T Gansevoort, Hiddo J L Heerspink, Meg Jardine, Bertram Kasiske, Anna Köttgen, Matthias Kretzler, Andrew S Levey, Valerie A Luyckx, Ravindra Mehta, Orson Moe, Gregorio Obrador, Neesh Pannu, Chirag R Parikh, Vlado Perkovic, Carol Pollock, Peter Stenvinkel, Katherine R Tuttle, David C Wheeler, Kai-Uwe Eckardt, Dwomoa Adu, Sanjay Kumar Agarwal, Mona Alrukhaimi, Hans-Joachim Anders, Gloria Ashuntantang, Shakti Basnet, Aminu K. Bello, Worawon Chailimpamontree, Ricardo Correa-Rotter, Jonathan Craig, Walter G. Douthat, Harold I. Feldman, Mohammad Reza Ganji, Guillermo Garcia-Garcia, Mohammed Benghanem Gharbi, David C. Harris, Vivekanand Jha, David W. Johnson, Rumeyza Kazancioglu, Robyn Langham, Zhi-Hong Liu, Ziad A. Massy, Masaomi Nangaku, Robert G. Nelson, Donal O'Donoghue, Ikechi Okpechi, Roberto Pecoits-Filho, Neil R. Powe, Giuseppe Remuzzi, Charlotte Roberts, Jerome Rossert, Laura Sola, Benedicte Stengel, Ernest K. Sumaili M, Yusuke Suzuki, Tetsuhiro Tanaka, Sajja Tatiyanupanwong, Bernadette Thomas, Katrin Uhlig, Robert Walker, Sarah L. White, Andrzej Wiecek, Chih-Wei Yang

Published in: The Lancet, Issue 390/10105, 2017, Page(s) 1888-1917, ISSN 0140-6736

DOI: 10.1016/S0140-6736(17)30788-2

A homozygous KAT2B variant modulates the clinical phenotype of ADD3 deficiency in humans and flies

Author(s): Sara Gonçalves, Julie Patat, Maria Clara Guida, Noelle Lachaussée, Christelle Arrondel, Martin Helmstädter, Olivia Boyer, Olivier Gribouval, Marie-Claire Gubler, Geraldine Mollet, Marlène Rio, Marina Charbit, Christine Bole-Feysot, Patrick Nitschke, Tobias B. Huber, Patricia G. Wheeler, Devon Haynes, Jane Juusola, Thierry Billette de Villemeur, Caroline Nava, Alexandra Afenjar, Boris Keren, Rolf Bodmer, Corinne Antignac, Matias Simons

Published in: PLOS Genetics, Issue 14/5, 2018, Page(s) e1007386, ISSN 1553-7404

DOI: 10.1371/journal.pgen.1007386

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Author(s): Paul Perco, Michelle Pena, Hiddo J.L. Heerspink, Gert Mayer

Published in: Kidney International Reports, Issue 4/2, 2019, Page(s) 212-221, ISSN 2468-0249

DOI: 10.1016/j.ekir.2018.12.001

Single-nephron proteomes connect morphology and function in proteinuric kidney disease

Author(s): Martin Höhne, Christian K. Frese, Florian Grahammer, Claudia Dafinger, Giuliano Ciarimboli, Linus Butt, Julia Binz, Matthias J. Hackl, Mahdieh Rahmatollahi, Martin Kann, Simon Schneider, Mehmet M. Altintas, Bernhard Schermer, Thomas Reinheckel, Heike Göbel, Jochen Reiser, Tobias B. Huber, Rafael Kramann, Tamina Seeger-Nukpezah, Max C. Liebau, Bodo B. Beck, Thomas Benzing, Andreas Beyer, Markus M. Rinschen

Published in: Kidney International, Issue 93/6, 2018, Page(s) 1308-1319, ISSN 0085-2538

DOI: 10.1016/j.kint.2017.12.012

Magnetic resonance imaging T1- and T2-mapping to assess renal structure and function: a systematic review and statement paper

Author(s): Marcos Wolf, Anneloes de Boer, Kanishka Sharma, Peter Boor, Tim Leiner, Gere Sunder-Plassmann, Ewald Moser, Anna Caroli, Neil Peter Jerome

Published in: Nephrology Dialysis Transplantation, Issue 33/suppl_2, 2018, Page(s) ii41-ii50, ISSN 0931-0509

DOI: 10.1093/ndt/gfy198

Podocyte GSK3 is an evolutionarily conserved critical regulator of kidney function

Author(s): J. A. Hurcombe, P. Hartley, A. C. Lay, L. Ni, J. J. Bedford, J. P. Leader, S. Singh, A. Murphy, C. L. Scudamore, E. Marquez, A. F. Barrington, V. Pinto, M. Marchetti, L.-F. Wong, J. Uney, M. A. Saleem, P. W. Mathieson, S. Patel, R. J. Walker, J. R. Woodgett, S. E. Quaggin, G. I. Welsh, R. J. M. Coward

Published in: Nature Communications, Issue 10/1, 2019, ISSN 2041-1723

DOI: 10.1038/s41467-018-08235-1

Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA

Author(s): Nicholas M Selby, Peter J Blankestijn, Peter Boor, Christian Combe, Kai-Uwe Eckardt, Eli Eikefjord, Nuria Garcia-Fernandez, Xavier Golay, Isky Gordon, Nicolas Grenier, Paul D Hockings, Jens D Jensen, Jaap A Joles, Philip A Kalra, Bernhard K Krämer, Patrick B Mark, Iosif A Mendichovszky, Olivera Nikolic, Aghogho Odudu, Albert C M Ong, Alberto Ortiz, Menno Pruijm, Giuseppe Remuzzi, Jarle Rørvik, Sophie de Seigneux, Roslyn J Simms, Janka Slatinska, Paul Summers, Maarten W Taal, Harriet C Thoeny, Jean-Paul Vallée, Marcos Wolf, Anna Caroli, Steven Sourbron

Published in: Nephrology Dialysis Transplantation, Issue 33/suppl_2, 2018, Page(s) ii4-ii14, ISSN 0931-0509

DOI: 10.1093/ndt/gfy152

Endogenous factors and mechanisms of renoprotection and renal repair

Author(s): Paul Perco, Gert Mayer

Published in: European Journal of Clinical Investigation, Issue 48/5, 2018, Page(s) e12914, ISSN 0014-2972

DOI: 10.1111/eci.12914

CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease

Author(s): Hans-Joachim Anders, Tobias B. Huber, Berend Isermann, Mario Schiffer

Published in: Nature Reviews Nephrology, Issue 14/6, 2018, Page(s) 361-377, ISSN 1759-5061

DOI: 10.1038/s41581-018-0001-y

Systems biology approaches to identify disease mechanisms and facilitate targeted therapy in the management of glomerular disease

Author(s): Habib Hamidi, Matthias Kretzler

Published in: Current Opinion in Nephrology and Hypertension, 2018, Page(s) 1, ISSN 1062-4821

DOI: 10.1097/MNH.0000000000000446

Protein and Molecular Characterization of a Clinically Compliant Amniotic Fluid Stem Cell-Derived Extracellular Vesicle Fraction Capable of Accelerating Muscle Regeneration Through Enhancement of Angiogenesis

Author(s): Ben Mellows, Robert Mitchell, Manuela Antonioli, Oliver Kretz, David Chambers, Marie-Theres Zeuner, Bernd Denecke, Luca Musante, Durrgah L. Ramachandra, Florence Debacq-Chainiaux, Harry Holthofer, Barbara Joch, Steve Ray, Darius Widera, Anna L. David, Tobias B. Huber, Joern Dengjel, Paolo De Coppi, Ketan Patel

Published in: Stem Cells and Development, Issue 26/18, 2017, Page(s) 1316-1333, ISSN 1547-3287

DOI: 10.1089/scd.2017.0089

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study

Author(s): Ellen M. Apperloo, Michelle J. Pena, Dick de Zeeuw, Petra Denig, Hiddo J. L. Heerspink

Published in: Diabetes, Obesity and Metabolism, Issue 20/6, 2018, Page(s) 1377-1383, ISSN 1462-8902

DOI: 10.1111/dom.13226

Using the Drosophila Nephrocyte to Model Podocyte Function and Disease

Author(s): Martin Helmstädter, Tobias B. Huber, Tobias Hermle

Published in: Frontiers in Pediatrics, Issue 5, 2017, ISSN 2296-2360

DOI: 10.3389/fped.2017.00262

Project information

BEAt-DKD

Grant agreement ID: 115974

Project website

Status

Ongoing project

Start date

1 September 2016
End date

31 August 2021

Funded under:

H2020-EU.3.1.7.

Overall budget:

€ 30 960 037
EU contribution

€ 15 085 937

Coordinated by:

LUNDS UNIVERSITET

Project information

BEAt-DKD

Grant agreement ID: 115974

Project website

Status

Ongoing project

Start date

1 September 2016
End date

31 August 2021

Funded under:

H2020-EU.3.1.7.

Overall budget:

€ 30 960 037
EU contribution

€ 15 085 937

Coordinated by:

LUNDS UNIVERSITET

Download

PDF

XML

Last update: 27 March 2017

Record number: 209459

CORDIS

Objective

Coordinator

Participants (30)

Project information

Periodic Reporting for period 2 - BEAt-DKD (Biomarker Enterprise to Attack DKD - Sofia ref.: 115974)

Project information

Deliverables

Publications

Project information

Project information

Share this page

Download